UPS (NYSE:UPS) today announced that its board of directors has appointed Angela Hwang to the board, effective immediately.
Hwang, age 54, is a member of Pfizer’s Executive Team and is Group President of the Pfizer Biopharmaceuticals Group, which comprises approximately 80% of Pfizer’s revenues. In this role, she leads more than 26,000 global colleagues and has responsibility for bringing over 600 innovative medicines and products to patients around the world.
“The UPS Board engaged in a thorough search and evaluation to find the right candidate for this role,” said UPS Executive Chairman of the Board David Abney. “Angela’s expertise in the healthcare sector will bring added talent to our Board as we oversee the company’s strategic growth efforts in this area.”
Hwang oversees seven commercial business units, which in 2019 generated nearly $40 billion in revenues, and impacted the lives of over 434 million patients across 125 countries. Together, these businesses strive to deliver transformational medicines that address major global health priorities in cancer, rare disease, inflammation & immunology, primary care, infectious diseases, and preventative care with vaccines.
“Angela is an outstanding, proven leader who brings added healthcare and global management experience to our Board,” said UPS Chief Executive Officer Carol Tomé. “We couldn’t be more thrilled to welcome Angela to the UPS Board of Directors during this time when UPS continues to expand its leadership in the healthcare logistics space, launching new healthcare services for UPS customers.”
Hwang is a 23-year veteran of Pfizer, and has held numerous leadership roles within the company. Prior to leading the Pfizer Biopharmaceuticals Group, she held more than 10 different positions in the company, spanning strategy, product development, marketing, sales, and general management. She is known as a transformational leader who drives for innovation and outstanding business performance and her experience covers a wide array of therapeutic areas and medicines in all lifecycle stages, as well as geographical breadth in both developed and emerging markets.
Hwang also sits on the boards of EFPIA (European Federation of Pharmaceutical Industries and Associations), as well as the Pfizer Foundation, a charitable organization that addresses global health challenges. She has been active in industry groups such as BIO (the Biotechnology Innovation Organization), where she previously co-chaired the Vaccines Policy Committee. In 2019, she was named to Crain’s Notable Women in Healthcare list.
Her appointment brings the total number of directors to 13. She is joining the Board’s Audit Committee.
Hwang received a Bachelor of Science in Microbiology and Biochemistry from the University of Cape Town, and an MBA from Cornell University.
UPS (NYSE: UPS), one of the world’s largest package delivery companies with 2019 revenue of $74 billion, provides a broad range of integrated logistics solutions for customers in more than 220 countries and territories. The company’s more than 500,000 employees embrace a strategy that is simply stated and powerfully executed: Customer First. People Led. Innovation Driven. UPS is committed to being a steward of the environment and positively contributing to the communities we serve around the world. UPS also takes a strong and unwavering stance in support of diversity, equity and inclusion. The company can be found on the Internet at www.ups.com, with more information at www.pressroom.ups.com and www.investors.ups.com.